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Oral mucositis, characterized by inflammatory response
and cell loss in the epithelial cells lining of the oral cavity,
is one of the most debilitating adverse effects of chemo-
therapy. In patients undergoing high-dose myeloablative
therapies, the incidence rate of oral mucositis is almost
100%, and in cancer patients undergoing standard-dose
chemotherapy the rate is 40e60%.1 Chemotherapeutic
agents with pronounced stomatotoxic effects are listed in
Table 1. Pain, odynophagia, dysguesia, and subsequent
malnutrition of oral mucositis have become a common
reason for decreasing the dosages of antineoplastic agents,
necessitating deference or cessation of antineoplastic
treatments, and preventing patients from optimal chemo-
therapy regimens, ultimately leading to higher mortality in
cancer patients. In addition, a vast variety of microorgan-
isms including bacteria, fungi, and viruses in the oral cavity
may enter the bloodstream because of the loss of mucosal
integrity, leading to systemic infections that interrupt
antineoplastic treatments, or even jeopardize patients’
lives.1
Historically, chemotherapy-induced mucositis was
thought to occur solely because of the basal cell damage of
the epithelium when drugs permeate into these cells via* Corresponding author. State Key Laboratory of Oral Diseases,
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http://dx.doi.org/10.1016/j.jfma.2013.10.014the submucosal blood supply. Recent advances in under-
standing its pathological mechanism indicate that it is the
consequence of a series of dynamic and interactive bio-
logical events involving the epithelia and submucosa in
response to stomatotoxic agents. A number of factors such
as treatment regimens, duration of treatment, dose in-
tensity, previous mucosatoxic treatments, the quality and
quantity of saliva, and lack of detoxification enzyme ac-
tivity, influence an individual’s risk of mucositis. The five-
phase pathobiological model of mucositis proposed by
Sonis2 includes: (1) the initiation phase characterized by
the formation of reactive oxygen species caused by
chemotherapy agents, which activates nuclear factor kappa
B; (2) the induction of messenger molecules such as inter-
leukin 6 and tumor necrosis factor alpha during the primary
damage response phase, which causes tissue inflammation
and apoptosis; (3) more inflammation and apoptosis during
the signal amplification phase as a consequence of the
amplification of messenger molecules; (4) loss of mucosal
integrity due to apoptosis during the ulcerative phase,
thereby promoting superficial bacterial translocation; and
(5) a self-resolving healing phase, characterized by cell
proliferation and differentiation.2 According to this model,
inflammation together with apoptosis lead to the loss of
integrity of the mucosal barrier, thereby promoting bacte-
rial translocation. The oral microbiota per se is thought to
play a small role in the initiation of oral mucositis.2
However, therapy options based on this pathobiological
model are not satisfactory. Chemotherapy-induced
oral mucositis is still a therapeutic challenge, necessi-
tating in-depth etiological studies that may lead to a& Formosan Medical Association. All rights reserved.
Table 1 Chemotherapeutic agents with pronounced sto-
matotoxic effects.
Actinomycin D Amsacrine Bleomycin
Chlorambucil Cytarabine Daunorubicin
Docetaxel Doxorubicin Etoposide
Floxuridine 5-Fluorouracil Methotrexate
Mitoxantrone Plicamycin Thioguanine
Vinblastine Vindesine
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gut microbiota with intestinal mucositis among cancer
patients undergoing chemotherapy has been recently re-
ported. A disturbed balance of intestinal microbiota
featuring a 100-fold increase of potentially pathogenic
aerobic enterococci and 10,000-fold decrease of anaerobic
bacteria has been discovered in patients with leukemia
who are vulnerable to intestinal mucositis.3 van Vliet
et al.4 have proposed that bacteria may play a dynamic
role in the development of chemotherapy-induced mucosal
injury within small intestine, by influencing: (1) the in-
flammatory progress and oxidative stress, (2) the consti-
tution of the mucus layer, (3) intestinal permeability, (4)
the expression and discharge of immune effector mole-
cules, and (5) the resistance toward harmful stimuli and
epithelial repair ability. In addition, promising results have
been obtained from the therapeutic use of probiotics to
alleviate chemotherapy-induced intestinal mucositis in
both animal model and clinical trials. All these findings
strongly indicate the involvement of microbial homeostasis
in the pathogenesis of chemotherapy-induced mucositis in
the intestine. However, the correlation of oral microbial
homeostasis and chemotherapy-induced oral mucositis is
not well documented.
Hypothesis
We hypothesized that chemotherapy may inhibit the
commensal bacteria within the oral cavity and induce an
ecological shift of oral microbiota toward a community
predominated by Gram-negative anaerobes exhibiting high
virulence phenotype, thus initiating a cascade of inflam-
matory processes involving the development of oral
mucositis.
Evaluation of the hypothesis
Commensal bacteria and oral homeostasis
The human oral cavity is a complex ecosystem character-
ized by the presence of a wide variety of bacterial colo-
nizers that coexist with each other and thrive in a dynamic
environment. Emerging evidence suggests that oral micro-
biota plays an important role in stimulating mucosal
epithelial cells and maintaining the mucosal barrier that
contributes to host defense. Streptococcus salivarius K12, a
commensal Gram-positive microbe, can stimulate an anti-
inflammatory response in oral epithelial cells and modu-
late genes associated with homeostasis.5 The cell wall
extract of an oral commensal mirobe, Fusobacterium
nucleatum, but not the more pathogenic Porphyromonasgingivalis, can induce the production of human b-defensin
2, contributing to innate immunity and host defense.6
Preliminary data obtained from culture-based methodolo-
gies have shown that antineoplastic agents can affect oral
microbial composition. Cytotoxic antineoplastic agents can
therefore compromise oral mucosal immunity, which can
lead to decreased Secretory Immunoglobulin A (SIgA)
secretion, salivary dysfunction, decreased salivary antimi-
crobial properties, and damage of the mucosal barrier lin-
ing the oral mucosa, further disrupting eubiosis of oral
microbiota. Therefore, we believe that oral mucositis may
occur when oral commensal bacteria are unable to offer
protection with the disruption of the ecological balance
during chemotherapy.
Pathways activated by disturbed oral microbiota during
mucositis
On the molecular level, the disturbed oral microbiota could
be involved in the inflammatory process of chemotherapy-
induced mucositis through two groups of receptors: Toll-like
receptors (TLRs) and nucleotide oligomerization domain
(NOD)-like receptors (NLRs). TLRs, which exist at the outer
membrane of the epithelium or intracellular vesicles,
function as pattern recognition receptors that recognize a
wide range of microbial pathogens. Activation of TLRs by
recognition of microbial components, such as peptido-
glycan, lipopolysaccharide, bacterial DNA, and protein
flagellin, triggers a cascade of cellular signals resulting in
the activation of nuclear factor kappa B, which leads to
inflammatory gene expression and development of the in-
flammatory response of mucosa.7 Moreover, after binding
with TLRs, bacteria are processed there and bacterial parts
are transported within cells, and then bind to NLRs, which
are a newfound group of intracellular cytosolic sensors
playing a crucial role in the regulation of the host inflam-
matory response. The best studied is NLRP3 (NLR family,
pyrin domain-containing 3), which recruitsdthrough the
adaptor protein ASCdcaspase-1 forming into a multiprotein
complex named the inflammasome. Once activated,
caspase-1 processes proinflammatory cytokines (such as
pro-IL-18 and pro-IL-1b) to their active and secreted forms,
thus regulating inflammatory response.8 Therefore, TLRs,
NLRs and their downstream pathways may be the potential
target of oral microbiota to initiate mucosa inflammation
among cancer patients undergoing chemotherapy.Implication of the hypothesis
Further research is warranted to clarify the pattern of
ecological shiftoforalmicrobiotaduringchemotherapyand its
relationship with oral mucositis using high-throughput meta-
genomic sequencing and global transcriptomic profiling. Once
the involvement of microbial ecological shift in the patho-
genesis of chemotherapy-inducedoralmucositis is elucidated,
it may contribute to the development of effective antimicro-
bial agents to specifically inhibit emerging pathogens or to
restore the homeostasis of oral cavity. A specifically targeted
antimicrobial peptide has been developed and proven to
effectively kill Streptococcus mutans while leaving other
bacteria unaffected. Thus, the development of narrow-
spectrum agents targeting the specific pathogens of oral
Oral microbiota 299mucositis is possible. Because the use of whole bacteria as
probiotics to restore oral dysbiosis could cause severe in-
fections in immunocompromised patients, the use of bacterial
parts to attenuate oral mucositis might also be promising.
Further in vitroand in vivoexperimentsareneeded tovalidate
these potential measures.
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